1
|
Zhang W, Wang H, Brandt DYC, Hu B, Sheng J, Wang M, Luo H, Li Y, Guo S, Sheng B, Zeng Q, Peng K, Zhao D, Jian S, Wu D, Wang J, Zhao G, Ren J, Shi W, van Esch JHM, Klingunga S, Nielsen R, Hong Y. The genetic architecture of phenotypic diversity in the Betta fish ( Betta splendens). SCIENCE ADVANCES 2022; 8:eabm4955. [PMID: 36129976 PMCID: PMC9491723 DOI: 10.1126/sciadv.abm4955] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/21/2021] [Accepted: 08/03/2022] [Indexed: 05/28/2023]
Abstract
The Betta fish displays a remarkable variety of phenotypes selected during domestication. However, the genetic basis underlying these traits remains largely unexplored. Here, we report a high-quality genome assembly and resequencing of 727 individuals representing diverse morphotypes of the Betta fish. We show that current breeds have a complex domestication history with extensive introgression with wild species. Using a genome-wide association study, we identify the genetic basis of multiple traits, including coloration patterns, the "Dumbo" phenotype with pectoral fin outgrowth, extraordinary enlargement of body size that we map to a major locus on chromosome 8, the sex determination locus that we map to dmrt1, and the long-fin phenotype that maps to the locus containing kcnj15. We also identify a polygenic signal related to aggression, involving multiple neural system-related genes such as esyt2, apbb2, and pank2. Our study provides a resource for developing the Betta fish as a genetic model for morphological and behavioral research in vertebrates.
Collapse
Affiliation(s)
- Wanchang Zhang
- School of Life Sciences, Nanchang University, Nanchang 330031, China
| | - Hongru Wang
- Department of Integrative Biology, University of California, Berkeley, Berkeley, CA 94720, USA
| | - Débora Y. C. Brandt
- Department of Integrative Biology, University of California, Berkeley, Berkeley, CA 94720, USA
| | - Beijuan Hu
- School of Life Sciences, Nanchang University, Nanchang 330031, China
| | - Junqing Sheng
- School of Life Sciences, Nanchang University, Nanchang 330031, China
| | - Mengnan Wang
- School of Life Sciences, Nanchang University, Nanchang 330031, China
| | - Haijiang Luo
- School of Life Sciences, Nanchang University, Nanchang 330031, China
| | - Yahui Li
- Department of Molecular, Cell and Systems Biology, University of California, Riverside, Riverside, CA 92521, USA
| | - Shujie Guo
- School of Life Sciences, Nanchang University, Nanchang 330031, China
| | - Bin Sheng
- School of Life Sciences, Nanchang University, Nanchang 330031, China
| | - Qi Zeng
- School of Life Sciences, Nanchang University, Nanchang 330031, China
| | - Kou Peng
- School of Life Sciences, Nanchang University, Nanchang 330031, China
| | - Daxian Zhao
- School of Life Sciences, Nanchang University, Nanchang 330031, China
| | - Shaoqing Jian
- School of Life Sciences, Nanchang University, Nanchang 330031, China
| | - Di Wu
- School of Life Sciences, Nanchang University, Nanchang 330031, China
| | - Junhua Wang
- School of Life Sciences, Nanchang University, Nanchang 330031, China
| | - Guang Zhao
- School of Life Sciences, Nanchang University, Nanchang 330031, China
| | - Jun Ren
- College of Animal Science, South China Agricultural University, Guangzhou 510642, China
| | - Wentian Shi
- Faculty of Philosophy, University of Tübingen, Tübingen 72074, Germany
| | - Joep H. M. van Esch
- Biology and Medical Laboratory Research, Rotterdam University of Applied Sciences, Rotterdam 3015, Netherlands
| | - Sirawut Klingunga
- Aquatic Molecular Genetics and Biotechnology Research Team, National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency (NSTDA), Pathum Thani 12120, Thailand
| | - Rasmus Nielsen
- Department of Integrative Biology, University of California, Berkeley, Berkeley, CA 94720, USA
- Globe Institute, University of Copenhagen, Copenhagen DK-1165, Denmark
| | - Yijiang Hong
- School of Life Sciences, Nanchang University, Nanchang 330031, China
- Key Laboratory of Aquatic Resources and Utilization, Nanchang University, Nanchang 330031, China
| |
Collapse
|
2
|
Santiago JA, Quinn JP, Potashkin JA. Physical Activity Rewires the Human Brain against Neurodegeneration. Int J Mol Sci 2022; 23:6223. [PMID: 35682902 PMCID: PMC9181322 DOI: 10.3390/ijms23116223] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2022] [Revised: 05/31/2022] [Accepted: 06/01/2022] [Indexed: 02/07/2023] Open
Abstract
Physical activity may offset cognitive decline and dementia, but the molecular mechanisms by which it promotes neuroprotection remain elusive. In the absence of disease-modifying therapies, understanding the molecular effects of physical activity in the brain may be useful for identifying novel targets for disease management. Here we employed several bioinformatic methods to dissect the molecular underpinnings of physical activity in brain health. Network analysis identified 'switch genes' associated with drastic hippocampal transcriptional changes in aged cognitively intact individuals. Switch genes are key genes associated with dramatic transcriptional changes and thus may play a fundamental role in disease pathogenesis. Switch genes are associated with protein processing pathways and the metabolic control of glucose, lipids, and fatty acids. Correlation analysis showed that transcriptional patterns associated with physical activity significantly overlapped and negatively correlated with those of neurodegenerative diseases. Functional analysis revealed that physical activity might confer neuroprotection in Alzheimer's (AD), Parkinson's (PD), and Huntington's (HD) diseases via the upregulation of synaptic signaling pathways. In contrast, in frontotemporal dementia (FTD) its effects are mediated by restoring mitochondrial function and energy precursors. Additionally, physical activity is associated with the downregulation of genes involved in inflammation in AD, neurogenesis in FTD, regulation of growth and transcriptional repression in PD, and glial cell differentiation in HD. Collectively, these findings suggest that physical activity directs transcriptional changes in the brain through different pathways across the broad spectrum of neurodegenerative diseases. These results provide new evidence on the unique and shared mechanisms between physical activity and neurodegenerative diseases.
Collapse
Affiliation(s)
| | | | - Judith A. Potashkin
- Center for Neurodegenerative Diseases and Therapeutics, Cellular and Molecular Pharmacology Department, The Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064, USA
| |
Collapse
|
3
|
Nagamatsu ST, Rompala G, Hurd YL, Núñez-Rios DL, Montalvo-Ortiz JL. CpH methylome analysis in human cortical neurons identifies novel gene pathways and drug targets for opioid use disorder. Front Psychiatry 2022; 13:1078894. [PMID: 36745154 PMCID: PMC9892724 DOI: 10.3389/fpsyt.2022.1078894] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/24/2022] [Accepted: 12/19/2022] [Indexed: 01/24/2023] Open
Abstract
INTRODUCTION DNA methylation (DNAm), an epigenetic mechanism, has been associated with opioid use disorder (OUD) in preclinical and human studies. However, most of the studies have focused on DNAm at CpG sites. DNAm at non-CpG sites (mCpHs, where H indicates A, T, or C) has been recently shown to have a role in gene regulation and to be highly abundant in neurons. However, its role in OUD is unknown. This work aims to evaluate mCpHs in the human postmortem orbital frontal cortex (OFC) in the context of OUD. METHODS A total of 38 Postmortem OFC samples were obtained from the VA Brain Bank (OUD = 12; Control = 26). mCpHs were assessed using reduced representation oxidative bisulfite sequencing in neuronal nuclei. Differential analysis was performed using the "methylkit" R package. Age, ancestry, postmortem interval, PTSD, and smoking status were included as covariates. Significant mCpHs were set at q-value < 0.05. Gene Ontology (GO) and KEGG enrichment analyses were performed for the annotated genes of all differential mCpH loci using String, ShinyGO, and amiGO software. Further, all annotated genes were analyzed using the Drug gene interaction database (DGIdb). RESULTS A total of 2,352 differentially methylated genome-wide significant mCpHs were identified in OUD, mapping to 2,081 genes. GO analysis of genes with differential mCpH loci showed enrichment for nervous system development (p-value = 2.32E-19). KEGG enrichment analysis identified axon guidance and glutamatergic synapse (FDR 9E-4-2.1E-2). Drug interaction analysis found 3,420 interactions between the annotated genes and drugs, identifying interactions with 15 opioid-related drugs, including lofexidine and tizanidine, both previously used for the treatment of OUD-related symptoms. CONCLUSION Our findings suggest a role of mCpHs for OUD in cortical neurons and reveal important biological pathways and drug targets associated with the disorder.
Collapse
Affiliation(s)
- Sheila T Nagamatsu
- Division of Human Genetics, Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.,VA Connecticut (VA CT) Healthcare Center, West Haven, CT, United States.,Clinical Neurosciences Division, U.S. Department of Veterans Affairs National Center of Posttraumatic Stress Disorder, West Haven, CT, United States
| | - Gregory Rompala
- Icahn School of Medicine at Mount Sinai, New York, NY, United States
| | - Yasmin L Hurd
- Icahn School of Medicine at Mount Sinai, New York, NY, United States
| | - Diana L Núñez-Rios
- Division of Human Genetics, Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.,VA Connecticut (VA CT) Healthcare Center, West Haven, CT, United States.,Clinical Neurosciences Division, U.S. Department of Veterans Affairs National Center of Posttraumatic Stress Disorder, West Haven, CT, United States
| | - Janitza L Montalvo-Ortiz
- Division of Human Genetics, Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.,VA Connecticut (VA CT) Healthcare Center, West Haven, CT, United States.,Clinical Neurosciences Division, U.S. Department of Veterans Affairs National Center of Posttraumatic Stress Disorder, West Haven, CT, United States
| | | |
Collapse
|
4
|
Visser PJ, Reus LM, Gobom J, Jansen I, Dicks E, Tsolaki M, Verhey FRJ, Popp J, Martinez-Lage P, Vandenberghe R, Lleó A, Molinuevo JL, Engelborghs S, Freund-Levi Y, Froelich L, Sleegers K, Dobricic V, Hong S, Lovestone S, Streffer J, Vos SJB, Bos I, Smit AB, Blennow K, Scheltens P, Teunissen CE, Bertram L, Zetterberg H, Tijms BM. Cerebrospinal fluid total tau levels indicate aberrant neuronal plasticity in Alzheimer's disease. MEDRXIV : THE PREPRINT SERVER FOR HEALTH SCIENCES 2020. [PMID: 33173883 DOI: 10.1101/2020.10.29.20211920] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Alzheimer's disease (AD) is characterised by abnormal amyloid beta and tau processing. Previous studies reported that cerebrospinal fluid (CSF) total tau (t-tau) levels vary between patients. Here we show that CSF t-tau variability is associated with distinct impairments in neuronal plasticity mediated by gene repression factors SUZ12 and REST. AD individuals with abnormal t-tau levels have increased CSF concentrations of plasticity proteins regulated by SUZ12 and REST. AD individuals with normal t-tau, on the contrary, have decreased concentrations of these plasticity proteins and increased concentrations in proteins associated with blood-brain and blood CSF-barrier dysfunction. Genomic analyses suggested that t-tau levels in part depend on genes involved in gene expression. The distinct plasticity abnormalities in AD as signaled by t-tau urge the need for personalised treatment.
Collapse
|
5
|
Cherian I, Venkatesh T, Paul PM. In silico prediction of UCLH1 disease-causing SNPs and its effects on protein stability. GENE REPORTS 2020. [DOI: 10.1016/j.genrep.2020.100677] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
6
|
Jin X, Gao J, Zheng R, Yu M, Ren Y, Yan T, Huang Y, Li Y. Antagonizing circRNA_002581-miR-122-CPEB1 axis alleviates NASH through restoring PTEN-AMPK-mTOR pathway regulated autophagy. Cell Death Dis 2020; 11:123. [PMID: 32054840 PMCID: PMC7018772 DOI: 10.1038/s41419-020-2293-7] [Citation(s) in RCA: 66] [Impact Index Per Article: 16.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2019] [Revised: 01/23/2020] [Accepted: 01/23/2020] [Indexed: 02/06/2023]
Abstract
Circular RNAs (circRNAs) have been shown to play critical roles in cancer biology, but their functions in nonalcoholic steatohepatitis (NASH) remain unexplored. Full length of circRNA_002581 was amplified and sequenced, followed by RNA immunoprecipitation, RNA-Fluorescence in Situ Hybridization and dual luciferase reporter gene analysis to confirm the existence of the circRNA_002581–miR-122–CPEB1 regulatory axis in vitro. CircRNA_002581 knockdown was used to study its roles in high concentration of free fatty acids-induced NASH-like cell model and a methionine and choline deficiency (MCD) diet-induced NASH mice model. Autophagy flux and related potential PTEN–AMPK–mTOR pathway were tested by western blot. CircRNA_002581 overexpression significantly relieved the inhibitory role of miR-122 on its target CPEB1 by sponging miR-122. CircRNA_002581 knockdown markedly attenuated lipid droplet accumulation, reduced the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), pro-inflammatory cytokines, apoptosis, H2O2, and increased ATP level in both mice and cellular models of NASH. Mechanistically, circRNA_002581 interference significantly rescue the defective autophagy evidenced by increased autophagosome number, upregulated LC3-II/I level, and decreased p62 level. Further chloroquine-mediated total autophagy inhibition antagonizes the protective effect of circRNA_002581 knockdown. Finally, CPEB1–PTEN–AMPK–mTOR pathway is shown to link the autophagy and circRNA_002581 knockdown-mediated NASH alleviation. CircRNA_002581–miR-122–CPEB1 axis actively participates in the pathogenesis of NASH through PTEN–AMPK–mTOR pathway-related autophagy suppression. Targeting circRNA_002581 is a potential therapeutic strategy for NASH through partial autophagy restoration.
Collapse
Affiliation(s)
- Xi Jin
- Department of Gastroenterology, the First Affiliated Hospital, School of Medicine, Zhejiang University, 310003, Hangzhou, China
| | - Jianguo Gao
- Department of Gastroenterology, the First Affiliated Hospital, School of Medicine, Zhejiang University, 310003, Hangzhou, China
| | - Ruoheng Zheng
- School of Clinical Medicine, Hangzhou Medical College, 310053, Hangzhou, China
| | - Mosang Yu
- Department of Gastroenterology, the First Affiliated Hospital, School of Medicine, Zhejiang University, 310003, Hangzhou, China
| | - Yue Ren
- School of Medicine, Zhejiang University, 310058, Hangzhou, China
| | - Tianlian Yan
- Department of Gastroenterology, the First Affiliated Hospital, School of Medicine, Zhejiang University, 310003, Hangzhou, China
| | - Yue Huang
- Department of Gastroenterology, the First Affiliated Hospital, School of Medicine, Zhejiang University, 310003, Hangzhou, China
| | - Youming Li
- Department of Gastroenterology, the First Affiliated Hospital, School of Medicine, Zhejiang University, 310003, Hangzhou, China.
| |
Collapse
|
7
|
Xia X, Wang Y, Huang Y, Zhang H, Lu H, Zheng JC. Exosomal miRNAs in central nervous system diseases: biomarkers, pathological mediators, protective factors and therapeutic agents. Prog Neurobiol 2019; 183:101694. [PMID: 31542363 PMCID: PMC7323939 DOI: 10.1016/j.pneurobio.2019.101694] [Citation(s) in RCA: 120] [Impact Index Per Article: 24.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2019] [Revised: 06/14/2019] [Accepted: 09/09/2019] [Indexed: 12/12/2022]
Abstract
Exosomes are small bilipid layer-enclosed extracellular vesicles that can be found in tissues and biological fluids. As a key cell-to-cell and distant communication mediator, exosomes are involved in various central nervous system (CNS) diseases, potentially through transferring their contents such as proteins, lipids and nucleic acids to the target cells. Exosomal miRNAs, which are small non-coding RNAs in the exosomes, are known to be more stable than free miRNAs and therefore have lasting effects on disease-related gene expressions. There are distinct profiles of exosomal miRNAs in different types of CNS diseases even before the onset of irreversible neurological damages, indicating that exosomal miRNAs within tissues and biological fluids could serve as promising biomarkers. Emerging evidence has also demonstrated the pathological effects of several exosomal miRNAs in CNS diseases via specific modulation of disease-related factors. Moreover, exosomes carry therapeutically beneficial miRNAs across the blood-brain-barrier, which can be exploited as a powerful drug delivery tool to help alleviating multiple CNS diseases. In this review, we summarize the recent progress made in understanding the biological roles of exosomal miRNAs as potential diagnostic biomarkers, pathological regulators, and therapeutic targets/drugs for CNS diseases. A comprehensive discussion of the main concerns and challenges for the applications of exosomal miRNAs in the clinical setting is also provided.
Collapse
Affiliation(s)
- Xiaohuan Xia
- Center for Translational Neurodegeneration and Regenerative Therapy, Shanghai Tenth People's Hospital affiliated to Tongji University School of Medicine, Shanghai 200072, China
| | - Yi Wang
- Center for Translational Neurodegeneration and Regenerative Therapy, Shanghai Tenth People's Hospital affiliated to Tongji University School of Medicine, Shanghai 200072, China
| | - Yunlong Huang
- Center for Translational Neurodegeneration and Regenerative Therapy, Shanghai Tenth People's Hospital affiliated to Tongji University School of Medicine, Shanghai 200072, China; Departments of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, 68198-5930, USA
| | - Han Zhang
- Second Military Medical University, Shanghai 200433, China
| | - Hongfang Lu
- Center for Translational Neurodegeneration and Regenerative Therapy, Shanghai Tenth People's Hospital affiliated to Tongji University School of Medicine, Shanghai 200072, China
| | - Jialin C Zheng
- Center for Translational Neurodegeneration and Regenerative Therapy, Shanghai Tenth People's Hospital affiliated to Tongji University School of Medicine, Shanghai 200072, China; Collaborative Innovation Center for Brain Science, Tongji University, Shanghai 200092, China; Departments of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, 68198-5930, USA.
| |
Collapse
|
8
|
Hussain R, Zubair H, Pursell S, Shahab M. Neurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic Approaches. Brain Sci 2018; 8:E177. [PMID: 30223579 PMCID: PMC6162719 DOI: 10.3390/brainsci8090177] [Citation(s) in RCA: 110] [Impact Index Per Article: 18.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2018] [Revised: 09/03/2018] [Accepted: 09/12/2018] [Indexed: 12/12/2022] Open
Abstract
Regeneration refers to regrowth of tissue in the central nervous system. It includes generation of new neurons, glia, myelin, and synapses, as well as the regaining of essential functions: sensory, motor, emotional and cognitive abilities. Unfortunately, regeneration within the nervous system is very slow compared to other body systems. This relative slowness is attributed to increased vulnerability to irreversible cellular insults and the loss of function due to the very long lifespan of neurons, the stretch of cells and cytoplasm over several dozens of inches throughout the body, insufficiency of the tissue-level waste removal system, and minimal neural cell proliferation/self-renewal capacity. In this context, the current review summarized the most common features of major neurodegenerative disorders; their causes and consequences and proposed novel therapeutic approaches.
Collapse
Affiliation(s)
- Rashad Hussain
- Center for Translational Neuromedicine, University of Rochester, NY 14642, USA.
| | - Hira Zubair
- Department of Animal Sciences, Quaid-i-Azam University, Islamabad 45320, Pakistan.
| | - Sarah Pursell
- Center for Translational Neuromedicine, University of Rochester, NY 14642, USA.
| | - Muhammad Shahab
- Department of Animal Sciences, Quaid-i-Azam University, Islamabad 45320, Pakistan.
| |
Collapse
|
9
|
Liu CC, Fang CP, Liu TH, Kuo HW, Liu SC, Wang SC, Chen ACH, Liu YL. APBB2 is associated with amphetamine use and plasma beta-amyloids in patients receiving methadone maintenance treatment. Prog Neuropsychopharmacol Biol Psychiatry 2018; 83:92-98. [PMID: 29330135 DOI: 10.1016/j.pnpbp.2018.01.008] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/26/2017] [Revised: 12/21/2017] [Accepted: 01/09/2018] [Indexed: 11/29/2022]
Abstract
APBB2, amyloid beta (A4) precursor protein-binding family B member 2, has been reported to be associated with opioid dependence. In this study, we reported the first time that the genetic variants in the APBB2 gene were associated with use of amphetamine in opioid dependent patients undergoing methadone maintenance treatment (MMT). 344 heroin-dependent patients undergoing MMT were recruited and assessed for use of amphetamine and opioids by urine toxicology, withdrawal severity, and side effects. DNAs were genome-widely genotyped for all patients. Single nucleotide polymorphisms (SNPs) in APBB2 were selected for association analyses for methadone treatment responses. Gene expression levels of APBB2 were measured by real-time polymerase chain reaction (PCR) in the EBV-transformed lymphoblastoids from patients. MMT patients who used amphetamine showed a significantly higher percentage of positive results in the urine morphine test (P=0.005), and insomnia (P=0.018). In single locus association analyses, SNPs rs3935357 and rs4861075 located at intron 6 were significantly associated with amphetamine use in both genotype and allele type (general linear model (GLM), P=0.0003, and 0.0002 for genotype, and 0.0003, and 0.002 for allele type, respectively). The major allele type carriers had twice risk of amphetamine use compared to the minor allele type carriers. Subjects with the TT genotype of rs4861075 showed significantly higher levels of APBB2 gene expression in both total (P=0.02) and long-form (P=0.037) than those with CC genotype. Detailed mechanisms underlying the association of APBB2 with amphetamine use and level of plasma amyloid beta in MMT patients require further investigation.
Collapse
Affiliation(s)
- Chia-Chen Liu
- Center for Neuropsychiatric Research, National Health Research Institutes, Miaoli County, Taiwan
| | - Chiu-Ping Fang
- Center for Neuropsychiatric Research, National Health Research Institutes, Miaoli County, Taiwan
| | - Tung-Hsia Liu
- Center for Neuropsychiatric Research, National Health Research Institutes, Miaoli County, Taiwan
| | - Hsiang-Wei Kuo
- Center for Neuropsychiatric Research, National Health Research Institutes, Miaoli County, Taiwan
| | - Shu Chi Liu
- Center for Neuropsychiatric Research, National Health Research Institutes, Miaoli County, Taiwan
| | - Sheng-Chang Wang
- Center for Neuropsychiatric Research, National Health Research Institutes, Miaoli County, Taiwan
| | - Andrew C H Chen
- Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, New York, USA; The Feinstein Institute for Medical Research, Hofstra Northwell School of Medicine at Hofstra University, Manhasset, New York, USA
| | - Yu-Li Liu
- Center for Neuropsychiatric Research, National Health Research Institutes, Miaoli County, Taiwan; Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan.
| |
Collapse
|
10
|
Giri M, Shah A, Upreti B, Rai JC. Unraveling the genes implicated in Alzheimer's disease. Biomed Rep 2017; 7:105-114. [PMID: 28781776 DOI: 10.3892/br.2017.927] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2016] [Accepted: 05/29/2017] [Indexed: 12/17/2022] Open
Abstract
Alzheimer's disease (AD) is a heterogeneous neurodegenerative disorder and it is the most common form of dementia in the elderly. Early onset AD is caused by mutations in three genes: Amyloid-β precursor protein, presenilin 1 (PSEN1) and PSEN2. Late onset AD (LOAD) is complex and apolipoprotein E is the only unanimously accepted genetic risk factor for its development. Various genes implicated in AD have been identified using advanced genetic technologies, however, there are many additional genes that remain unidentified. The present review highlights the genetics of early and LOAD and summarizes the genes involved in different signaling pathways. This may provide insight into neurodegenerative disease research and will facilitate the development of effective strategies to combat AD.
Collapse
Affiliation(s)
- Mohan Giri
- National Center for Rheumatic Diseases, Ratopul, Kathmandu 44600, Nepal
| | - Abhilasha Shah
- National Center for Rheumatic Diseases, Ratopul, Kathmandu 44600, Nepal
| | - Bibhuti Upreti
- National Center for Rheumatic Diseases, Ratopul, Kathmandu 44600, Nepal
| | | |
Collapse
|
11
|
Zhong X, Liu MY, Sun XH, Wei MJ. Association between ABCB1 polymorphisms and haplotypes and Alzheimer's disease: a meta-analysis. Sci Rep 2016; 6:32708. [PMID: 27600024 PMCID: PMC5013326 DOI: 10.1038/srep32708] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2016] [Accepted: 08/12/2016] [Indexed: 01/04/2023] Open
Abstract
Although several epidemiological studies have investigated the association between ATP-binding cassette subfamily B member 1 (ABCB1) gene polymorphisms and Alzheimer's disease (AD) susceptibility, controversial results exist. Here, we performed a meta-analysis to assess whether ABCB1 polymorphisms 3435C > T (rs1045642), 2677G > T/A (rs2032582), 1236C > T (rs1128503) and haplotypes were associated with AD risk. Nine independent publications were included and analyzed. Crude odds ratio (OR) and 95% confidence interval (CI) were applied to investigate the strength of the association. Sensitivity analysis was conducted to measure the robustness of our analysis. A funnel plot and trim and fill method were used to test and adjust for publication bias. The results showed a significant association between the 3435C > T single nucleotide polymorphism (SNP) and AD susceptibility (CT vs. CC: OR = 1.24, 95% CI = 1.06-1.45, P = 0.01; CT + TT vs. CC: OR = 1.21, 95% CI = 1.04-1.41, P = 0.01) in the total population, as well as in Caucasian subgroup. The 2677G > T/A SNP was related to a decreased AD risk in Caucasian subgroup (TT + TA + AA vs. GT + GA + GG: OR = 0.68, 95% CI = 0.47-0.98, P = 0.04). Moreover, the ABCB1 haplotype analysis showed that the 1236T/2677T/3435C haplotype was associated with a higher risk of AD (OR = 1.99, 95% CI = 1.24-3.18, P = 0.00). Our results suggest that the ABCB1 3435C > T SNP, the 2677G > T/A SNP and 1236T/2677T/3435C haplotype are significantly associated with AD susceptibility.
Collapse
Affiliation(s)
- Xin Zhong
- School of Pharmacy, Department of Pharmacology, China Medical University, Shenyang, Liaoning 110122, China
| | - Ming-Yan Liu
- School of Pharmacy, Department of Pharmacology, China Medical University, Shenyang, Liaoning 110122, China
| | - Xiao-Hong Sun
- Department of Neurology, the Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning 110032, China
| | - Min-Jie Wei
- School of Pharmacy, Department of Pharmacology, China Medical University, Shenyang, Liaoning 110122, China
| |
Collapse
|
12
|
Role of long purine stretches in controlling the expression of genes associated with neurological disorders. Gene 2015; 572:175-83. [DOI: 10.1016/j.gene.2015.07.007] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2015] [Revised: 06/17/2015] [Accepted: 07/02/2015] [Indexed: 11/22/2022]
|
13
|
Bae JH, Kim JG, Heo K, Yang K, Kim TO, Yi JM. Identification of radiation-induced aberrant hypomethylation in colon cancer. BMC Genomics 2015; 16:56. [PMID: 25887185 PMCID: PMC4342812 DOI: 10.1186/s12864-015-1229-6] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2014] [Accepted: 01/09/2015] [Indexed: 12/22/2022] Open
Abstract
Background Exposure to ionizing radiation (IR) results in the simultaneous activation or downregulation of multiple signaling pathways that play critical roles in cell type-specific control of survival or death. IR is a well-known genotoxic agent and human carcinogen that induces cellular damage through direct and indirect mechanisms. However, its impact on epigenetic mechanisms has not been elucidated, and more specifically, little information is available regarding genome-wide DNA methylation changes in cancer cells after IR exposure. Recently, genome-wide DNA methylation profiling technology using the Illumina HumanMethylation450K platform has emerged that allows us to query >450,000 loci within the genome. This improved technology is capable of identifying genome-wide DNA methylation changes in CpG islands and other CpG island-associated regions. Results In this study, we employed this technology to test the hypothesis that exposure to IR not only induces differential DNA methylation patterns at a genome-wide level, but also results in locus- and gene-specific DNA methylation changes. We screened for differential DNA methylation changes in colorectal cancer cells after IR exposure with 2 and 5 Gy. Twenty-nine genes showed radiation-induced hypomethylation in colon cancer cells, and of those, seven genes showed a corresponding increase in gene expression by reverse transcriptase polymerase chain reaction (RT-PCR). In addition, we performed chromatin immunoprecipitation (ChIP) to confirm that the DNA-methyltransferase 1 (DNMT1) level associated with the promoter regions of these genes correlated with their methylation level and gene expression changes. Finally, we used a gene ontology (GO) database to show that a handful of hypomethylated genes induced by IR are associated with a variety of biological pathways related to cancer. Conclusion We identified alterations in global DNA methylation patterns and hypomethylation at specific cancer-related genes following IR exposure, which suggests that radiation exposure plays a critical role in conferring epigenetic alterations in cancer. Electronic supplementary material The online version of this article (doi:10.1186/s12864-015-1229-6) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Jin-Han Bae
- Research Center, Dongnam Institute of Radiological & Medical Sciences (DIRAMS), Busan, 619-953, South Korea.
| | - Joong-Gook Kim
- Research Center, Dongnam Institute of Radiological & Medical Sciences (DIRAMS), Busan, 619-953, South Korea.
| | - Kyu Heo
- Research Center, Dongnam Institute of Radiological & Medical Sciences (DIRAMS), Busan, 619-953, South Korea.
| | - Kwangmo Yang
- Research Center, Dongnam Institute of Radiological & Medical Sciences (DIRAMS), Busan, 619-953, South Korea. .,Department of Radiation Oncology, Korea Institute of Radiological and Medical Sciences, Seoul, 139-709, Korea.
| | - Tae-Oh Kim
- Department of Internal Medicine, Inje University Haeundae Paik hospital, Busan, 612-896, South Korea.
| | - Joo Mi Yi
- Research Center, Dongnam Institute of Radiological & Medical Sciences (DIRAMS), Busan, 619-953, South Korea.
| |
Collapse
|
14
|
Romano JD, Tharp WG, Sarkar IN. Adapting simultaneous analysis phylogenomic techniques to study complex disease gene relationships. J Biomed Inform 2015; 54:10-38. [PMID: 25592479 DOI: 10.1016/j.jbi.2015.01.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2014] [Revised: 01/02/2015] [Accepted: 01/05/2015] [Indexed: 12/11/2022]
Abstract
The characterization of complex diseases remains a great challenge for biomedical researchers due to the myriad interactions of genetic and environmental factors. Network medicine approaches strive to accommodate these factors holistically. Phylogenomic techniques that can leverage available genomic data may provide an evolutionary perspective that may elucidate knowledge for gene networks of complex diseases and provide another source of information for network medicine approaches. Here, an automated method is presented that leverages publicly available genomic data and phylogenomic techniques, resulting in a gene network. The potential of approach is demonstrated based on a case study of nine genes associated with Alzheimer Disease, a complex neurodegenerative syndrome. The developed technique, which is incorporated into an update to a previously described Perl script called "ASAP," was implemented through a suite of Ruby scripts entitled "ASAP2," first compiles a list of sequence-similarity based orthologues using PSI-BLAST and a recursive NCBI BLAST+ search strategy, then constructs maximum parsimony phylogenetic trees for each set of nucleotide and protein sequences, and calculates phylogenetic metrics (Incongruence Length Difference between orthologue sets, partitioned Bremer support values, combined branch scores, and Robinson-Foulds distance) to provide an empirical assessment of evolutionary conservation within a given genetic network. In addition to the individual phylogenetic metrics, ASAP2 provides results in a way that can be used to generate a gene network that represents evolutionary similarity based on topological similarity (the Robinson-Foulds distance). The results of this study demonstrate the potential for using phylogenomic approaches that enable the study of multiple genes simultaneously to provide insights about potential gene relationships that can be studied within a network medicine framework that may not have been apparent using traditional, single-gene methods. Furthermore, the results provide an initial integrated evolutionary history of an Alzheimer Disease gene network and identify potentially important co-evolutionary clustering that may warrant further investigation.
Collapse
Affiliation(s)
- Joseph D Romano
- Department of Microbiology and Molecular Genetics, University of Vermont, Burlington, VT 05405, USA
| | - William G Tharp
- Department of Medicine, Endocrinology Unit, University of Vermont, Burlington, VT 05405, USA
| | - Indra Neil Sarkar
- Department of Microbiology and Molecular Genetics, University of Vermont, Burlington, VT 05405, USA; Center for Clinical and Translational Science, University of Vermont, Burlington, VT 05405, USA; Department of Computer Science, University of Vermont, Burlington, VT 05405, USA.
| |
Collapse
|
15
|
Genome-wide association study of opioid dependence: multiple associations mapped to calcium and potassium pathways. Biol Psychiatry 2014; 76:66-74. [PMID: 24143882 PMCID: PMC3992201 DOI: 10.1016/j.biopsych.2013.08.034] [Citation(s) in RCA: 165] [Impact Index Per Article: 16.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/31/2013] [Revised: 07/29/2013] [Accepted: 08/27/2013] [Indexed: 01/15/2023]
Abstract
BACKGROUND We report a genome-wide association study (GWAS) of two populations, African-American and European-American (AA, EA) for opioid dependence (OD) in three sets of subjects, to identify pathways, genes, and alleles important in OD risk. METHODS The design employed three phases (on the basis of separate sample collections). Phase 1 included our discovery GWAS dataset consisting of 5697 subjects (58% AA) diagnosed with opioid and/or other substance dependence and control subjects. Subjects were genotyped with the Illumina OmniQuad microarray, yielding 890,000 single nucleotide polymorphisms (SNPs) suitable for analysis. Additional genotypes were imputed with the 1000 Genomes reference panel. Top-ranked findings were further evaluated in Phase 2 by incorporating information from the publicly available Study of Addiction: Genetics and Environment dataset, with GWAS data from 4063 subjects (32% AA). In Phase 3, the most significant SNPs from Phase 2 were genotyped in 2549 independent subjects (32% AA). Analyses were performed with case-control and ordinal trait designs. RESULTS Most significant results emerged from the AA subgroup. Genome-wide-significant associations (p < 5.0 × 10(-8)) were observed with SNPs from multiple loci-KCNG2*rs62103177 was most significant after combining results from datasets in every phase of the study. The most compelling results were obtained with genes involved in potassium signaling pathways (e.g., KCNC1 and KCNG2). Pathway analysis also implicated genes involved in calcium signaling and long-term potentiation. CONCLUSIONS This is the first study to identify risk variants for OD with GWAS. Our results strongly implicate risk pathways and provide insights into novel therapeutic and prevention strategies and might biologically bridge OD and other non-substance dependence psychiatric traits where similar pathways have been implicated.
Collapse
|
16
|
Golanska E, Sieruta M, Gresner SM, Pfeffer A, Chodakowska-Zebrowska M, Sobow TM, Klich I, Mossakowska M, Szybinska A, Barcikowska M, Liberski PP. APBB2 genetic polymorphisms are associated with severe cognitive impairment in centenarians. Exp Gerontol 2013; 48:391-4. [PMID: 23384821 DOI: 10.1016/j.exger.2013.01.013] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2012] [Revised: 12/20/2012] [Accepted: 01/08/2013] [Indexed: 11/28/2022]
Abstract
APBB2 gene encodes for β-amyloid precursor protein-binding family B member 2, (APBB2, FE65-like, FE65L1), an adaptor protein binding to the cytoplasmatic domain of β-amyloid precursor protein (βAPP). Over-expression of APBB2 promotes formation of β-amyloid (Aβ), the main constituent of senile plaques. Polymorphisms within APBB2 gene have been proposed as candidate risk factors for Alzheimer's disease. However, their association with longevity has never been investigated. Here we present the first attempt to analyze APBB2 polymorphisms in centenarians. We used a PCR-RFLP method to analyze two intronic nucleotide substitutions: hCV1558625 (rs17443013) and rs13133980. We found no differences in genotype or allele distribution between centenarians and young controls. After stratification of centenarians upon their cognitive performance, the APBB2 rs13133980 G allele was over-represented in centenarians with severe cognitive impairment compared to individuals without this disability. Also the hCV1558625-rs13133980 AG haplotype increased relative risk for severe cognitive impairment in centenarians. Our results support the concept of APBB2 polymorphism association with cognitive performance in the oldest age.
Collapse
Affiliation(s)
- Ewa Golanska
- Department of Molecular Pathology and Neuropathology, Medical University of Lodz, 8/10 Czechoslowacka St., 92-216 Lodz, Poland.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
The FAS gene, brain volume, and disease progression in Alzheimer's disease. Alzheimers Dement 2009; 6:118-24. [PMID: 19766542 DOI: 10.1016/j.jalz.2009.05.663] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2009] [Revised: 05/04/2009] [Accepted: 05/04/2009] [Indexed: 11/23/2022]
Abstract
OBJECTIVE We sought to identify single-nucleotide polymorphisms (SNPs) associated with Alzheimer's disease (AD) progression and brain volume. METHODS Ninety-seven SNPs were genotyped in 243 subjects from a longitudinal study of healthy aging. Subjects who received a diagnosis of cognitive impairment (CI) at any study visit (before their most recent visit) and had DNA in the study's DNA bank were included. Progression of AD was defined as the duration from onset of CI to diagnosis of AD. Association of each of the 97 SNPs with AD progression was tested via Cox model. Those SNPs meeting a criterion of nominal significance (P < 0.05) for association with AD progression were reassessed to account for multiple testing by repeating the marker selection process in 10,000 random permutations. Next, the association between the one SNP that survived the multiple-testing adjustment and brain volume was determined by multiple regression analysis in a subgroup of subjects for whom magnetic-resonance imaging (MRI)-derived brain-volume data were available. Brain volumes were adjusted for age at MRI, gender, and time from MRI to onset of CI. RESULTS The minor allele of rs1468063 in the FAS gene, which is member 6 of the tumor necrosis factor receptor superfamily, was significantly associated with faster AD progression after adjustment for multiple testing (P(permutation) = 0.049). The same allele in rs1468063 was associated with smaller brain volumes and larger ventricular volumes (P = 0.02 and 0.04, respectively). CONCLUSIONS The FAS gene, which plays a role in apoptosis, may be associated with AD by modulating the apoptosis and neuronal loss secondary to AD neuropathology.
Collapse
|
18
|
Analysis of APBB2 gene polymorphisms in sporadic Alzheimer’s disease. Neurosci Lett 2008; 447:164-6. [DOI: 10.1016/j.neulet.2008.10.003] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2008] [Revised: 09/26/2008] [Accepted: 10/02/2008] [Indexed: 11/16/2022]
|
19
|
Lacritin and other new proteins of the lacrimal functional unit. Exp Eye Res 2008; 88:848-58. [PMID: 18840430 DOI: 10.1016/j.exer.2008.09.002] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2008] [Revised: 09/04/2008] [Accepted: 09/08/2008] [Indexed: 12/21/2022]
Abstract
The lacrimal functional unit (LFU) is defined by the 2007 International Dry Eye WorkShop as 'an integrated system comprising the lacrimal glands, ocular surface (cornea, conjunctiva and meibomian glands) and lids, and the sensory and motor nerves that connect them'. The LFU maintains a healthy ocular surface primarily through a properly functioning tear film that provides protection, lubrication, and an environment for corneal epithelial cell renewal. LFU cells express thousands of proteins. Over 200 new LFU proteins have been discovered in the last decade. Lacritin is a new LFU-specific growth factor in human tears that flows through ducts to target corneal epithelial cells on the ocular surface. When applied topically in rabbits, lacritin appears to increase the volume of basal tear secretion. Lacritin is one of only a handful of tear proteins preliminarily reported to be downregulated in blepharitis and in two dry eye syndromes. Computational analysis predicts an ordered C-terminal domain that binds the corneal epithelial cell surface proteoglycan syndecan-1 (SDC1) and is required for lacritin's low nanomolar mitogenic activity. The lacritin-binding site on the N-terminus of SDC1 is exposed by heparanase. Heparanase is constitutively expressed by the corneal epithelium and appears to be a normal constituent of tears. Binding triggers rapid signaling to downstream NFAT and mTOR. A wealth of other new proteins, originally designated as hypothetical when first identified by genomic sequencing, are expressed by the human LFU including: ALS2CL, ARHGEF19, KIAA1109, PLXNA1, POLG, WIPI1 and ZMIZ2. Their demonstrated or implied roles in human genetic disease or basic cellular functions are fuel for new investigation. Addressing topical areas in ocular surface physiology with new LFU proteins may reveal interesting new biological mechanisms and help get to the heart of ocular surface dysfunction.
Collapse
|
20
|
Li Y, Grupe A, Rowland C, Holmans P, Segurado R, Abraham R, Jones L, Catanese J, Ross D, Mayo K, Martinez M, Hollingworth P, Goate A, Cairns NJ, Racette BA, Perlmutter JS, O'Donovan MC, Morris JC, Brayne C, Rubinsztein DC, Lovestone S, Thal LJ, Owen MJ, Williams J. Evidence that common variation in NEDD9 is associated with susceptibility to late-onset Alzheimer's and Parkinson's disease. Hum Mol Genet 2008; 17:759-67. [PMID: 18063669 DOI: 10.1093/hmg/ddm348] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Late-onset Alzheimer's disease (LOAD) and Parkinson's disease (PD) are the most common neurodegenerative disorders and in both diseases susceptibility is known to be influenced by genes. We set out to identify novel susceptibility genes for LOAD by performing a large scale, multi-tiered association study testing 4692 single nucleotide polymorphism (SNPs). We identified a SNP within a putative transcription factor binding site in the NEDD9 gene (neural precursor cell expressed, developmentally down-regulated), that shows good evidence of association with disease risk in four out of five LOAD samples [N = 3521, P = 5.38x10(-6), odds ratio (OR) = 1.38 (1.20-1.59)] and in addition, we observed a similar pattern of association in two PD sample sets [N = 1464, P = 0.0145, OR =1.31 (1.05-1.62)]. In exploring a potential mechanism for the association, we observed that expression of NEDD9 and APOE show a strong inverse correlation in the hippocampus of Alzheimer's cases. These data implicate NEDD9 as a novel susceptibility gene for LOAD and possibly PD.
Collapse
Affiliation(s)
- Yonghong Li
- Celera, 1401 Harbor Bay Parkway, Alameda, CA 94502, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Li Y, Grupe A. Genetics of late-onset Alzheimer’s disease: progress and prospect. Pharmacogenomics 2007; 8:1747-55. [DOI: 10.2217/14622416.8.12.1747] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Genetic susceptibility factors for late-onset Alzheimer’s disease remain largely elusive, with the exception of apolipoprotein E4 (APOE e4) as the only confirmed genetic risk factor. Numerous other putative risk markers have been proposed, although all suffer inconsistent replication. These results suggest that modest effect sizes are likely to be the norm for non-APOE-related factors. This unsettling situation has been similar to other complex diseases such as diabetes and cardiovascular diseases until very recently, when a spate of new, although weak, genetic markers has been convincingly linked to these conditions. If we assume that multiple weak factors, together with APOE e4, account for the genetic contribution to late-onset Alzheimer’s disease risk, it will require the concerted efforts of the greater Alzheimer’s genetics community to pool existing genetic resources and/or data to identify novel genetic risk factors that are genuine. Increased confidence in the disease-associated factors will provide the foundation to develop better diagnostic and prognostic tests, select new drug targets and, perhaps, elucidate pharmacogenetic markers that assist in making the best treatment decisions.
Collapse
Affiliation(s)
- Yonghong Li
- Celera, 1401 Harbor Bay Parkway, Alameda, CA 94502, USA
| | | |
Collapse
|
22
|
Grupe A, Abraham R, Li Y, Rowland C, Hollingworth P, Morgan A, Jehu L, Segurado R, Stone D, Schadt E, Karnoub M, Nowotny P, Tacey K, Catanese J, Sninsky J, Brayne C, Rubinsztein D, Gill M, Lawlor B, Lovestone S, Holmans P, O'Donovan M, Morris JC, Thal L, Goate A, Owen MJ, Williams J. Evidence for novel susceptibility genes for late-onset Alzheimer's disease from a genome-wide association study of putative functional variants. Hum Mol Genet 2007; 16:865-73. [PMID: 17317784 DOI: 10.1093/hmg/ddm031] [Citation(s) in RCA: 186] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
This study sets out to identify novel susceptibility genes for late-onset Alzheimer's disease (LOAD) in a powerful set of samples from the UK and USA (1808 LOAD cases and 2062 controls). Allele frequencies of 17 343 gene-based putative functional single nucleotide polymorphisms (SNPs) were tested for association with LOAD in a discovery case-control sample from the UK. A tiered strategy was used to follow-up significant variants from the discovery sample in four independent sample sets. Here, we report the identification of several candidate SNPs that show significant association with LOAD. Three of the identified markers are located on chromosome 19 (meta-analysis: full sample P = 6.94E - 81 to 0.0001), close to the APOE gene and exhibit linkage disequilibrium (LD) with the APOEepsilon4 and epsilon2/3 variants (0.09 < D'<1). Two of the three SNPs can be regarded as study-wide significant (expected number of false positives reaching the observed significance level less than 0.05 per study). Sixteen additional SNPs show evidence for association with LOAD [P = 0.0010-0.00006; odds ratio (OR) = 1.07-1.45], several of which map to known linkage regions, biological candidate genes and novel genes. Four SNPs not in LD with APOE show a false positive rate of less than 2 per study, one of which shows study-wide suggestive evidence taking account of 17 343 tests. This is a missense mutation in the galanin-like peptide precursor gene (P = 0.00005, OR = 1.2, false positive rate = 0.87).
Collapse
Affiliation(s)
- Andrew Grupe
- Celera Diagnostics, 1401 Harbor Bay Parkway, Alameda, CA 94502, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Kimura R, Kamino K, Yamamoto M, Nuripa A, Kida T, Kazui H, Hashimoto R, Tanaka T, Kudo T, Yamagata H, Tabara Y, Miki T, Akatsu H, Kosaka K, Funakoshi E, Nishitomi K, Sakaguchi G, Kato A, Hattori H, Uema T, Takeda M. The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease. Hum Mol Genet 2007; 16:15-23. [PMID: 17135279 DOI: 10.1093/hmg/ddl437] [Citation(s) in RCA: 184] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
We scanned throughout chromosome 21 to assess genetic associations with late-onset Alzheimer disease (AD) using 374 Japanese patients and 375 population-based controls, because trisomy 21 is known to be associated with early deposition of beta-amyloid (Abeta) in the brain. Among 417 markers spanning 33 Mb, 22 markers showed associations with either the allele or the genotype frequency (P < 0.05). Logistic regression analysis with age, sex and apolipoprotein E (APOE)-epsilon4 dose supported genetic risk of 17 markers, of which eight markers were linked to the SAMSN1, PRSS7, NCAM2, RUNX1, DYRK1A and KCNJ6 genes. In logistic regression, the DYRK1A (dual-specificity tyrosine-regulated kinase 1A) gene, located in the Down syndrome critical region, showed the highest significance [OR = 2.99 (95% CI: 1.72-5.19), P = 0.001], whereas the RUNX1 gene showed a high odds ratio [OR = 23.3 (95% CI: 2.76-196.5), P = 0.038]. DYRK1A mRNA level in the hippocampus was significantly elevated in patients with AD when compared with pathological controls (P < 0.01). DYRK1A mRNA level was upregulated along with an increase in the Abeta-level in the brain of transgenic mice, overproducing Abeta at 9 months of age. In neuroblastoma cells, Abeta induced an increase in the DYRK1A transcript, which also led to tau phosphorylation at Thr212 under the overexpression of tau. Therefore, the upregulation of DYRK1A transcription results from Abeta loading, further leading to tau phosphorylation. Our result indicates that DYRK1A could be a key molecule bridging between beta-amyloid production and tau phosphorylation in AD.
Collapse
Affiliation(s)
- Ryo Kimura
- Department of Psychiatry, Osaka University Graduate School of Medicine, 2-2-D3 Yamadaoka, Suita, Osaka 565-0871, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Li Y, Schrodi S, Rowland C, Tacey K, Catanese J, Grupe A. Genetic evidence for ubiquitin-specific proteases USP24 and USP40 as candidate genes for late-onset Parkinson disease. Hum Mutat 2006; 27:1017-23. [PMID: 16917932 DOI: 10.1002/humu.20382] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
Linkage studies have defined susceptibility regions for late-onset Parkinson disease (PD) on chromosomes 1 and 2, but specific genetic variants have not been definitively identified. Here we report the results of a case-control study to identify disease-associated single nucleotide polymorphisms (SNPs) in these loci. In the initial phase of our study, we genotyped two putative functional SNPs in ubiquitin-specific protease 24 (USP24), a biological candidate gene within the chromosome 1 linkage region, and scanned the chromosome 2 linkage peak with 43 SNPs in a sample set of 224 PD cases and 186 matched controls. Both USP24 SNPs were significantly associated with disease risk (p = 0.0037 for rs1165222:T > C, p.Thr195ILe, and p = 0.037 for rs13312:C > G, a SNP in the 3'-untranslated region), and one marker, rs1048603:C > T, p.Arg1123Cys, in USP40 was significant from the chromosome 2 scan (p = 0.038). Further genotyping of the region surrounding these initial markers led us to identify 19 additional SNPs with strong disease association. In the second phase, we genotyped the 22 significant markers in an additional 110 cases and 162 controls, which together with part of the initial sample set (201 cases and 149 controls) constitute an expanded sample set of 311 age- and gender-matched case-control pairs. Twenty-one markers were significant in the expanded sample set (most significant allelic p-value: 0.0006 for rs287235:C > G on chromosome 1, and 0.005 for rs838552:T > C on chromosome 2), and six SNPs in USP24 remained significant after conservatively adjusting for testing 27 markers (pBonferroni = 0.017-0.049). It is unlikely that population stratification contributed to this finding, as population stratification was undetectable in our sample set using 78 null markers. Our data suggest that genetic variants in USP24 and USP40 affect the risk for late-onset PD, which is consistent with the predicted role of the ubiquitination pathway in PD etiology.
Collapse
Affiliation(s)
- Yonghong Li
- Celera Diagnostics, Alameda, California 94502, USA.
| | | | | | | | | | | |
Collapse
|
25
|
Li Y, Grupe A, Rowland C, Nowotny P, Kauwe JSK, Smemo S, Hinrichs A, Tacey K, Toombs TA, Kwok S, Catanese J, White TJ, Maxwell TJ, Hollingworth P, Abraham R, Rubinsztein DC, Brayne C, Wavrant-De Vrièze F, Hardy J, O'Donovan M, Lovestone S, Morris JC, Thal LJ, Owen M, Williams J, Goate A. DAPK1 variants are associated with Alzheimer's disease and allele-specific expression. Hum Mol Genet 2006; 15:2560-8. [PMID: 16847012 DOI: 10.1093/hmg/ddl178] [Citation(s) in RCA: 102] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Genetic factors play an important role in the etiology of late-onset Alzheimer's disease (LOAD). We tested gene-centric single nucleotide polymorphisms (SNPs) on chromosome 9 and identified two SNPs in the death-associated protein kinase, DAPK1, that show significant association with LOAD. SNP rs4878104 was significantly associated with LOAD in our discovery case-control sample set (WU) and replicated in each of two initial validation case-control sample sets (P<0.05, UK1, SD). The risk-allele frequency of this SNP showed a similar direction in three other case-control sample sets. A meta-analysis of the six sample sets combined, totaling 2012 cases and 2336 controls, showed an allelic P-value of 0.0016 and an odds ratio (OR) of 0.87 (95%CI: 0.79-0.95). Minor allele homozygotes had a consistently lower risk than major allele homozygotes in the discovery and initial two replication sample sets, which remained significant in the meta-analysis of all six sample sets (OR=0.7, 95%CI: 0.58-0.85), whereas the risk for heterozygous subjects was not significantly different from that of major allele homozygotes. A second SNP, rs4877365, which is in high linkage disequilibrium with rs4878104 (r2=0.64), was also significantly associated with LOAD (meta P=0.0017 in the initial three sample sets). Furthermore, DAPK1 transcripts show differential allelic gene expression, and both rs4878104 and rs4877365 were significantly associated with DAPK1 allele-specific expression (P=0.015 to <0.0001). These data suggest that genetic variation in DAPK1 modulates susceptibility to LOAD.
Collapse
|
26
|
Sokol DK, Chen D, Farlow MR, Dunn DW, Maloney B, Zimmer JA, Lahiri DK. High levels of Alzheimer beta-amyloid precursor protein (APP) in children with severely autistic behavior and aggression. J Child Neurol 2006; 21:444-9. [PMID: 16948926 DOI: 10.1177/08830738060210062201] [Citation(s) in RCA: 82] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Autism is characterized by restricted, repetitive behaviors and impairment in socialization and communication. Although no neuropathologic substrate underlying autism has been found, the findings of brain overgrowth via neuroimaging studies and increased levels of brain-derived neurotrophic factor (BDNF) in neuropathologic and blood studies favor an anabolic state. We examined acetylcholinesterase, plasma neuronal proteins, secreted beta-amyloid precursor protein (APP), and amyloid-beta 40 and amyloid-beta 42 peptides in children with and without autism. Children with severe autism and aggression expressed secreted beta-amyloid precursor protein at two or more times the levels of children without autism and up to four times more than children with mild autism. There was a trend for children with autism to show higher levels of secreted beta-amyloid precursor protein and nonamyloidogenic secreted beta-amyloid precursor protein and lower levels of amyloid-beta 40 compared with controls. This favors an increased alpha-secretase pathway in autism (anabolic), opposite to what is seen in Alzheimer disease. Additionally, a complex relationship between age, acetylcholinesterase, and plasma neuronal markers was found.
Collapse
Affiliation(s)
- Deborah K Sokol
- Department of Neurology, Indiana University School of Medicine, 702 Barnhill Drive, Indianapolis, IN 46202, USA.
| | | | | | | | | | | | | |
Collapse
|
27
|
Healy DG, Abou-Sleiman PM, Casas JP, Ahmadi KR, Lynch T, Gandhi S, Muqit MMK, Foltynie T, Barker R, Bhatia KP, Quinn NP, Lees AJ, Gibson JM, Holton JL, Revesz T, Goldstein DB, Wood NW. UCHL-1is not a Parkinson's disease susceptibility gene. Ann Neurol 2006; 59:627-33. [PMID: 16450370 DOI: 10.1002/ana.20757] [Citation(s) in RCA: 91] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
OBJECTIVE The UCHL-1 gene is widely cited as a susceptibility factor for sporadic Parkinson's disease (PD). The strongest evidence comes from a meta-analysis of small studies that reported the S18Y polymorphism as protective against PD, after pooling studies of white and Asian subjects. Here, we present data that challenge this association. METHODS In a new large case-control study in white individuals (3,023 subjects), the S18Y variant was not protective against PD under any genetic model of inheritance. Similarly, a more powerful haplotype-tagging approach did not detect other associated variants. RESULTS Finally, in an updated S18Y-PD meta-analysis (6,594 subjects), no significant association was observed under additive, recessive, or dominant models (odds ratio = 1.00 [95% confidence interval: 0.74-1.33]; odds ratio = 1.01 [95% confidence interval: 0.76-1.35]; and odds ratio = 0.96 [95% confidence interval: 0.86-1.08], respectively), and a cumulative meta-analysis showed a trend toward a null effect. INTERPRETATION Based on the current evidence, the UCHL-1 gene does not exhibit a protective effect in PD.
Collapse
Affiliation(s)
- Daniel G Healy
- Department of Molecular Neuroscience, Institute of Neurology, University College London, London, United Kingdom.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Sillén A, Forsell C, Lilius L, Axelman K, Björk BF, Onkamo P, Kere J, Winblad B, Graff C. Genome scan on Swedish Alzheimer's disease families. Mol Psychiatry 2006; 11:182-6. [PMID: 16288313 DOI: 10.1038/sj.mp.4001772] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Alzheimer's disease (AD) is an age-related disease, which affects approximately 40% of the population at an age above 90 years. The heritability is estimated to be greater than 60% and there are rare autosomal dominant forms indicating a significant genetic influence on the disease process. Despite the successes in the early 1990s when four genes were identified, which directly cause the disease (APP, PSEN1 and PSEN2) or greatly increase the risk of disease development (APOE), it has proved exceedingly difficult to identify additional genes involved in the pathogenesis. However, several linkage and association studies have repeatedly supported the presence of susceptibility genes on chromosomes (chrms) 9, 10 and 12. The study populations have, however, mostly been of great genetic heterogeneity, and this may have contributed to the meagre successes in identifying the disease associated genetic variants. In this study, we have performed a genome wide linkage study on 71 AD families from the relatively genetically homogeneous Swedish population where it is also possible to study the genetic ancestry in public databases. We have performed nonparametric linkage analyses in the total family material as well as stratified the families with respect to the presence or absence of APOE varepsilon4. Our results suggest that the families included in this study are tightly linked to the APOE region, but do not show evidence of linkage to the previously reported linkages on chrms 9, 10 and 12. Instead, we observed the next highest LOD score on chromosome 5q35 in the total material. Further, the data suggest that the major fraction of families linked to this region is APOE varepsilon4 positive.
Collapse
Affiliation(s)
- A Sillén
- Department Neurotec, Karolinska Institutet Sumitomo Pharmaceuticals Alzheimer Center, Karolinska Institutet, Novum, Huddinge, Sweden
| | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Grupe A, Li Y, Rowland C, Nowotny P, Hinrichs AL, Smemo S, Kauwe JSK, Maxwell TJ, Cherny S, Doil L, Tacey K, van Luchene R, Myers A, Wavrant-De Vrièze F, Kaleem M, Hollingworth P, Jehu L, Foy C, Archer N, Hamilton G, Holmans P, Morris CM, Catanese J, Sninsky J, White TJ, Powell J, Hardy J, O’Donovan M, Lovestone S, Jones L, Morris JC, Thal L, Owen M, Williams J, Goate A. A scan of chromosome 10 identifies a novel locus showing strong association with late-onset Alzheimer disease. Am J Hum Genet 2006; 78:78-88. [PMID: 16385451 PMCID: PMC1380225 DOI: 10.1086/498851] [Citation(s) in RCA: 134] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2005] [Accepted: 10/11/2005] [Indexed: 12/21/2022] Open
Abstract
Strong evidence of linkage to late-onset Alzheimer disease (LOAD) has been observed on chromosome 10, which implicates a wide region and at least one disease-susceptibility locus. Although significant associations with several biological candidate genes on chromosome 10 have been reported, these findings have not been consistently replicated, and they remain controversial. We performed a chromosome 10-specific association study with 1,412 gene-based single-nucleotide polymorphisms (SNPs), to identify susceptibility genes for developing LOAD. The scan included SNPs in 677 of 1,270 known or predicted genes; each gene contained one or more markers, about half (48%) of which represented putative functional mutations. In general, the initial testing was performed in a white case-control sample from the St. Louis area, with 419 LOAD cases and 377 age-matched controls. Markers that showed significant association in the exploratory analysis were followed up in several other white case-control sample sets to confirm the initial association. Of the 1,397 markers tested in the exploratory sample, 69 reached significance (P < .05). Five of these markers replicated at P < .05 in the validation sample sets. One marker, rs498055, located in a gene homologous to RPS3A (LOC439999), was significantly associated with Alzheimer disease in four of six case-control series, with an allelic P value of .0001 for a meta-analysis of all six samples. One of the case-control samples with significant association to rs498055 was derived from the linkage sample (P = .0165). These results indicate that variants in the RPS3A homologue are associated with LOAD and implicate this gene, adjacent genes, or other functional variants (e.g., noncoding RNAs) in the pathogenesis of this disorder.
Collapse
Affiliation(s)
- Andrew Grupe
- Celera Diagnostics, Alameda, CA; Departments of Psychiatry, Neurology, Biology, and Genetics, Washington University, St. Louis; National Institute on Aging (NIA), Bethesda; Biostatistics and Bioinformatics Unit and Department of Psychological Medicine, Wales College of Medicine, Cardiff University, Cardiff; Department of Neuroscience, Institute of Psychiatry, King’s College London, London; Institute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; and Department of Neurosciences, University of California–San Diego, La Jolla
| | - Yonghong Li
- Celera Diagnostics, Alameda, CA; Departments of Psychiatry, Neurology, Biology, and Genetics, Washington University, St. Louis; National Institute on Aging (NIA), Bethesda; Biostatistics and Bioinformatics Unit and Department of Psychological Medicine, Wales College of Medicine, Cardiff University, Cardiff; Department of Neuroscience, Institute of Psychiatry, King’s College London, London; Institute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; and Department of Neurosciences, University of California–San Diego, La Jolla
| | - Charles Rowland
- Celera Diagnostics, Alameda, CA; Departments of Psychiatry, Neurology, Biology, and Genetics, Washington University, St. Louis; National Institute on Aging (NIA), Bethesda; Biostatistics and Bioinformatics Unit and Department of Psychological Medicine, Wales College of Medicine, Cardiff University, Cardiff; Department of Neuroscience, Institute of Psychiatry, King’s College London, London; Institute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; and Department of Neurosciences, University of California–San Diego, La Jolla
| | - Petra Nowotny
- Celera Diagnostics, Alameda, CA; Departments of Psychiatry, Neurology, Biology, and Genetics, Washington University, St. Louis; National Institute on Aging (NIA), Bethesda; Biostatistics and Bioinformatics Unit and Department of Psychological Medicine, Wales College of Medicine, Cardiff University, Cardiff; Department of Neuroscience, Institute of Psychiatry, King’s College London, London; Institute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; and Department of Neurosciences, University of California–San Diego, La Jolla
| | - Anthony L. Hinrichs
- Celera Diagnostics, Alameda, CA; Departments of Psychiatry, Neurology, Biology, and Genetics, Washington University, St. Louis; National Institute on Aging (NIA), Bethesda; Biostatistics and Bioinformatics Unit and Department of Psychological Medicine, Wales College of Medicine, Cardiff University, Cardiff; Department of Neuroscience, Institute of Psychiatry, King’s College London, London; Institute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; and Department of Neurosciences, University of California–San Diego, La Jolla
| | - Scott Smemo
- Celera Diagnostics, Alameda, CA; Departments of Psychiatry, Neurology, Biology, and Genetics, Washington University, St. Louis; National Institute on Aging (NIA), Bethesda; Biostatistics and Bioinformatics Unit and Department of Psychological Medicine, Wales College of Medicine, Cardiff University, Cardiff; Department of Neuroscience, Institute of Psychiatry, King’s College London, London; Institute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; and Department of Neurosciences, University of California–San Diego, La Jolla
| | - John S. K. Kauwe
- Celera Diagnostics, Alameda, CA; Departments of Psychiatry, Neurology, Biology, and Genetics, Washington University, St. Louis; National Institute on Aging (NIA), Bethesda; Biostatistics and Bioinformatics Unit and Department of Psychological Medicine, Wales College of Medicine, Cardiff University, Cardiff; Department of Neuroscience, Institute of Psychiatry, King’s College London, London; Institute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; and Department of Neurosciences, University of California–San Diego, La Jolla
| | - Taylor J. Maxwell
- Celera Diagnostics, Alameda, CA; Departments of Psychiatry, Neurology, Biology, and Genetics, Washington University, St. Louis; National Institute on Aging (NIA), Bethesda; Biostatistics and Bioinformatics Unit and Department of Psychological Medicine, Wales College of Medicine, Cardiff University, Cardiff; Department of Neuroscience, Institute of Psychiatry, King’s College London, London; Institute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; and Department of Neurosciences, University of California–San Diego, La Jolla
| | - Sara Cherny
- Celera Diagnostics, Alameda, CA; Departments of Psychiatry, Neurology, Biology, and Genetics, Washington University, St. Louis; National Institute on Aging (NIA), Bethesda; Biostatistics and Bioinformatics Unit and Department of Psychological Medicine, Wales College of Medicine, Cardiff University, Cardiff; Department of Neuroscience, Institute of Psychiatry, King’s College London, London; Institute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; and Department of Neurosciences, University of California–San Diego, La Jolla
| | - Lisa Doil
- Celera Diagnostics, Alameda, CA; Departments of Psychiatry, Neurology, Biology, and Genetics, Washington University, St. Louis; National Institute on Aging (NIA), Bethesda; Biostatistics and Bioinformatics Unit and Department of Psychological Medicine, Wales College of Medicine, Cardiff University, Cardiff; Department of Neuroscience, Institute of Psychiatry, King’s College London, London; Institute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; and Department of Neurosciences, University of California–San Diego, La Jolla
| | - Kristina Tacey
- Celera Diagnostics, Alameda, CA; Departments of Psychiatry, Neurology, Biology, and Genetics, Washington University, St. Louis; National Institute on Aging (NIA), Bethesda; Biostatistics and Bioinformatics Unit and Department of Psychological Medicine, Wales College of Medicine, Cardiff University, Cardiff; Department of Neuroscience, Institute of Psychiatry, King’s College London, London; Institute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; and Department of Neurosciences, University of California–San Diego, La Jolla
| | - Ryan van Luchene
- Celera Diagnostics, Alameda, CA; Departments of Psychiatry, Neurology, Biology, and Genetics, Washington University, St. Louis; National Institute on Aging (NIA), Bethesda; Biostatistics and Bioinformatics Unit and Department of Psychological Medicine, Wales College of Medicine, Cardiff University, Cardiff; Department of Neuroscience, Institute of Psychiatry, King’s College London, London; Institute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; and Department of Neurosciences, University of California–San Diego, La Jolla
| | - Amanda Myers
- Celera Diagnostics, Alameda, CA; Departments of Psychiatry, Neurology, Biology, and Genetics, Washington University, St. Louis; National Institute on Aging (NIA), Bethesda; Biostatistics and Bioinformatics Unit and Department of Psychological Medicine, Wales College of Medicine, Cardiff University, Cardiff; Department of Neuroscience, Institute of Psychiatry, King’s College London, London; Institute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; and Department of Neurosciences, University of California–San Diego, La Jolla
| | - Fabienne Wavrant-De Vrièze
- Celera Diagnostics, Alameda, CA; Departments of Psychiatry, Neurology, Biology, and Genetics, Washington University, St. Louis; National Institute on Aging (NIA), Bethesda; Biostatistics and Bioinformatics Unit and Department of Psychological Medicine, Wales College of Medicine, Cardiff University, Cardiff; Department of Neuroscience, Institute of Psychiatry, King’s College London, London; Institute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; and Department of Neurosciences, University of California–San Diego, La Jolla
| | - Mona Kaleem
- Celera Diagnostics, Alameda, CA; Departments of Psychiatry, Neurology, Biology, and Genetics, Washington University, St. Louis; National Institute on Aging (NIA), Bethesda; Biostatistics and Bioinformatics Unit and Department of Psychological Medicine, Wales College of Medicine, Cardiff University, Cardiff; Department of Neuroscience, Institute of Psychiatry, King’s College London, London; Institute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; and Department of Neurosciences, University of California–San Diego, La Jolla
| | - Paul Hollingworth
- Celera Diagnostics, Alameda, CA; Departments of Psychiatry, Neurology, Biology, and Genetics, Washington University, St. Louis; National Institute on Aging (NIA), Bethesda; Biostatistics and Bioinformatics Unit and Department of Psychological Medicine, Wales College of Medicine, Cardiff University, Cardiff; Department of Neuroscience, Institute of Psychiatry, King’s College London, London; Institute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; and Department of Neurosciences, University of California–San Diego, La Jolla
| | - Luke Jehu
- Celera Diagnostics, Alameda, CA; Departments of Psychiatry, Neurology, Biology, and Genetics, Washington University, St. Louis; National Institute on Aging (NIA), Bethesda; Biostatistics and Bioinformatics Unit and Department of Psychological Medicine, Wales College of Medicine, Cardiff University, Cardiff; Department of Neuroscience, Institute of Psychiatry, King’s College London, London; Institute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; and Department of Neurosciences, University of California–San Diego, La Jolla
| | - Catherine Foy
- Celera Diagnostics, Alameda, CA; Departments of Psychiatry, Neurology, Biology, and Genetics, Washington University, St. Louis; National Institute on Aging (NIA), Bethesda; Biostatistics and Bioinformatics Unit and Department of Psychological Medicine, Wales College of Medicine, Cardiff University, Cardiff; Department of Neuroscience, Institute of Psychiatry, King’s College London, London; Institute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; and Department of Neurosciences, University of California–San Diego, La Jolla
| | - Nicola Archer
- Celera Diagnostics, Alameda, CA; Departments of Psychiatry, Neurology, Biology, and Genetics, Washington University, St. Louis; National Institute on Aging (NIA), Bethesda; Biostatistics and Bioinformatics Unit and Department of Psychological Medicine, Wales College of Medicine, Cardiff University, Cardiff; Department of Neuroscience, Institute of Psychiatry, King’s College London, London; Institute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; and Department of Neurosciences, University of California–San Diego, La Jolla
| | - Gillian Hamilton
- Celera Diagnostics, Alameda, CA; Departments of Psychiatry, Neurology, Biology, and Genetics, Washington University, St. Louis; National Institute on Aging (NIA), Bethesda; Biostatistics and Bioinformatics Unit and Department of Psychological Medicine, Wales College of Medicine, Cardiff University, Cardiff; Department of Neuroscience, Institute of Psychiatry, King’s College London, London; Institute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; and Department of Neurosciences, University of California–San Diego, La Jolla
| | - Peter Holmans
- Celera Diagnostics, Alameda, CA; Departments of Psychiatry, Neurology, Biology, and Genetics, Washington University, St. Louis; National Institute on Aging (NIA), Bethesda; Biostatistics and Bioinformatics Unit and Department of Psychological Medicine, Wales College of Medicine, Cardiff University, Cardiff; Department of Neuroscience, Institute of Psychiatry, King’s College London, London; Institute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; and Department of Neurosciences, University of California–San Diego, La Jolla
| | - Chris M. Morris
- Celera Diagnostics, Alameda, CA; Departments of Psychiatry, Neurology, Biology, and Genetics, Washington University, St. Louis; National Institute on Aging (NIA), Bethesda; Biostatistics and Bioinformatics Unit and Department of Psychological Medicine, Wales College of Medicine, Cardiff University, Cardiff; Department of Neuroscience, Institute of Psychiatry, King’s College London, London; Institute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; and Department of Neurosciences, University of California–San Diego, La Jolla
| | - Joseph Catanese
- Celera Diagnostics, Alameda, CA; Departments of Psychiatry, Neurology, Biology, and Genetics, Washington University, St. Louis; National Institute on Aging (NIA), Bethesda; Biostatistics and Bioinformatics Unit and Department of Psychological Medicine, Wales College of Medicine, Cardiff University, Cardiff; Department of Neuroscience, Institute of Psychiatry, King’s College London, London; Institute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; and Department of Neurosciences, University of California–San Diego, La Jolla
| | - John Sninsky
- Celera Diagnostics, Alameda, CA; Departments of Psychiatry, Neurology, Biology, and Genetics, Washington University, St. Louis; National Institute on Aging (NIA), Bethesda; Biostatistics and Bioinformatics Unit and Department of Psychological Medicine, Wales College of Medicine, Cardiff University, Cardiff; Department of Neuroscience, Institute of Psychiatry, King’s College London, London; Institute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; and Department of Neurosciences, University of California–San Diego, La Jolla
| | - Thomas J. White
- Celera Diagnostics, Alameda, CA; Departments of Psychiatry, Neurology, Biology, and Genetics, Washington University, St. Louis; National Institute on Aging (NIA), Bethesda; Biostatistics and Bioinformatics Unit and Department of Psychological Medicine, Wales College of Medicine, Cardiff University, Cardiff; Department of Neuroscience, Institute of Psychiatry, King’s College London, London; Institute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; and Department of Neurosciences, University of California–San Diego, La Jolla
| | - John Powell
- Celera Diagnostics, Alameda, CA; Departments of Psychiatry, Neurology, Biology, and Genetics, Washington University, St. Louis; National Institute on Aging (NIA), Bethesda; Biostatistics and Bioinformatics Unit and Department of Psychological Medicine, Wales College of Medicine, Cardiff University, Cardiff; Department of Neuroscience, Institute of Psychiatry, King’s College London, London; Institute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; and Department of Neurosciences, University of California–San Diego, La Jolla
| | - John Hardy
- Celera Diagnostics, Alameda, CA; Departments of Psychiatry, Neurology, Biology, and Genetics, Washington University, St. Louis; National Institute on Aging (NIA), Bethesda; Biostatistics and Bioinformatics Unit and Department of Psychological Medicine, Wales College of Medicine, Cardiff University, Cardiff; Department of Neuroscience, Institute of Psychiatry, King’s College London, London; Institute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; and Department of Neurosciences, University of California–San Diego, La Jolla
| | - Michael O’Donovan
- Celera Diagnostics, Alameda, CA; Departments of Psychiatry, Neurology, Biology, and Genetics, Washington University, St. Louis; National Institute on Aging (NIA), Bethesda; Biostatistics and Bioinformatics Unit and Department of Psychological Medicine, Wales College of Medicine, Cardiff University, Cardiff; Department of Neuroscience, Institute of Psychiatry, King’s College London, London; Institute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; and Department of Neurosciences, University of California–San Diego, La Jolla
| | - Simon Lovestone
- Celera Diagnostics, Alameda, CA; Departments of Psychiatry, Neurology, Biology, and Genetics, Washington University, St. Louis; National Institute on Aging (NIA), Bethesda; Biostatistics and Bioinformatics Unit and Department of Psychological Medicine, Wales College of Medicine, Cardiff University, Cardiff; Department of Neuroscience, Institute of Psychiatry, King’s College London, London; Institute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; and Department of Neurosciences, University of California–San Diego, La Jolla
| | - Lesley Jones
- Celera Diagnostics, Alameda, CA; Departments of Psychiatry, Neurology, Biology, and Genetics, Washington University, St. Louis; National Institute on Aging (NIA), Bethesda; Biostatistics and Bioinformatics Unit and Department of Psychological Medicine, Wales College of Medicine, Cardiff University, Cardiff; Department of Neuroscience, Institute of Psychiatry, King’s College London, London; Institute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; and Department of Neurosciences, University of California–San Diego, La Jolla
| | - John C. Morris
- Celera Diagnostics, Alameda, CA; Departments of Psychiatry, Neurology, Biology, and Genetics, Washington University, St. Louis; National Institute on Aging (NIA), Bethesda; Biostatistics and Bioinformatics Unit and Department of Psychological Medicine, Wales College of Medicine, Cardiff University, Cardiff; Department of Neuroscience, Institute of Psychiatry, King’s College London, London; Institute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; and Department of Neurosciences, University of California–San Diego, La Jolla
| | - Leon Thal
- Celera Diagnostics, Alameda, CA; Departments of Psychiatry, Neurology, Biology, and Genetics, Washington University, St. Louis; National Institute on Aging (NIA), Bethesda; Biostatistics and Bioinformatics Unit and Department of Psychological Medicine, Wales College of Medicine, Cardiff University, Cardiff; Department of Neuroscience, Institute of Psychiatry, King’s College London, London; Institute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; and Department of Neurosciences, University of California–San Diego, La Jolla
| | - Michael Owen
- Celera Diagnostics, Alameda, CA; Departments of Psychiatry, Neurology, Biology, and Genetics, Washington University, St. Louis; National Institute on Aging (NIA), Bethesda; Biostatistics and Bioinformatics Unit and Department of Psychological Medicine, Wales College of Medicine, Cardiff University, Cardiff; Department of Neuroscience, Institute of Psychiatry, King’s College London, London; Institute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; and Department of Neurosciences, University of California–San Diego, La Jolla
| | - Julie Williams
- Celera Diagnostics, Alameda, CA; Departments of Psychiatry, Neurology, Biology, and Genetics, Washington University, St. Louis; National Institute on Aging (NIA), Bethesda; Biostatistics and Bioinformatics Unit and Department of Psychological Medicine, Wales College of Medicine, Cardiff University, Cardiff; Department of Neuroscience, Institute of Psychiatry, King’s College London, London; Institute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; and Department of Neurosciences, University of California–San Diego, La Jolla
| | - Alison Goate
- Celera Diagnostics, Alameda, CA; Departments of Psychiatry, Neurology, Biology, and Genetics, Washington University, St. Louis; National Institute on Aging (NIA), Bethesda; Biostatistics and Bioinformatics Unit and Department of Psychological Medicine, Wales College of Medicine, Cardiff University, Cardiff; Department of Neuroscience, Institute of Psychiatry, King’s College London, London; Institute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; and Department of Neurosciences, University of California–San Diego, La Jolla
| |
Collapse
|
30
|
Dillen K, Annaert W. A Two Decade Contribution of Molecular Cell Biology to the Centennial of Alzheimer's Disease: Are We Progressing Toward Therapy? INTERNATIONAL REVIEW OF CYTOLOGY 2006; 254:215-300. [PMID: 17148000 DOI: 10.1016/s0074-7696(06)54005-7] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Alzheimer's disease (AD), described for the first time 100 years ago, is a neurodegenerative disease characterized by two neuropathological hallmarks: neurofibrillary tangles containing hyperphosphorylated tau and senile plaques. These lesions are likely initiated by an imbalance between production and clearance of amyloid beta, leading to increased oligomerization of these peptides, formation of amyloid plaques in the brain of the patient, and final dementia. Amyloid beta is generated from amyloid precursor protein (APP) by subsequent beta- and gamma-secretase cleavage, the latter being a multiprotein complex consisting of presenilin-1 or -2, nicastrin, APH-1, and PEN-2. Alternatively, APP can be cleaved by alpha- and gamma-secretase, precluding the production of Abeta. In this review, we discuss the major breakthroughs during the past two decades of molecular cell biology and the current genetic and cell biological state of the art on APP proteolysis, including structure-function relationships and subcellular localization. Finally, potential directions for cell biological research toward the development of AD therapies are briefly discussed.
Collapse
Affiliation(s)
- Katleen Dillen
- Laboratory for Membrane Trafficking, Center for Human Genetics/VIB1104 & KULeuven, Gasthuisberg O&N1, B-3000 Leuven, Belgium
| | | |
Collapse
|